Peptide Research News - Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody ... - MarketWatch (press release)

Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody ... - MarketWatch (press release)

Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody ... MarketWatch (press release) BOTHELL, Wash., May 7, 2012 /PRNewswire via COMTEX/ -- Alder BioPharmaceuticals Inc. today announced the initiation of a Phase 1 clinical study of its antibody therapeutic candidate, ALD403, targeting the calcitonin gene-related peptide (CGRP) for ... and more »

Click Here to read the entire article...